Trial · NCT03374956
Individualized Obesity Pharmacotherapy
NCT03374956, Phase 3, Completed, Mayo Clinic; results first posted 2023-07-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Individualized Obesity Pharmacotherapy. Trials, record NCT03374956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03374956
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Individualized Obesity Pharmacotherapy
- NCT number
- NCT03374956
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 193 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Obesity
- Interventions
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
- First posted
- 2017-12-15
- Last updated
- 2023-07-18
- Results first posted
- 2023-07-18
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Total Body Weight | baseline to 12 weeks | Percent change in body weight |
| Secondary | Percentage of Responders | baseline to 12 weeks | Percentage of participants who loss 5% or more of total body weight |
| Secondary | Percentage of Responders | baseline to 12 weeks | Percentage of participants with at least 10% total body weight loss |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Total Body Weight | baseline to 12 weeks | percent change | MEDIAN | |
| SECONDARY | Percentage of Responders | baseline to 12 weeks | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Responders | baseline to 12 weeks | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Total Body Weight | Intervention Group | -7.7 | Inter-Quartile Range -11 to -4.7 | percent change | |
| Change in Total Body Weight | Control Group | -6.5 | Inter-Quartile Range -11 to -2.3 | percent change | |
| Percentage of Responders | Intervention Group | 81 | percentage of participants | ||
| Percentage of Responders | Control Group | 80 | percentage of participants | ||
| Percentage of Responders | Intervention Group | 44 | percentage of participants | ||
| Percentage of Responders | Control Group | 40 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention Group | 93 | |
| Overall Study | STARTED | Control Group | 100 | |
| Overall Study | COMPLETED | Intervention Group | 93 | |
| Overall Study | COMPLETED | Control Group | 100 | |
| Overall Study | NOT COMPLETED | Intervention Group | 0 | |
| Overall Study | NOT COMPLETED | Control Group | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | During study | Gastrointestinal disorders | Intervention Group | 23 | 93 | 23 |
| other | During study | Gastrointestinal disorders | Control Group | 25 | 100 | 25 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention Group | 0 | 93 |
| Total, all-cause mortality | Control Group | 0 | 100 |
| Total, other adverse events | Intervention Group | 23 | 93 |
| Total, other adverse events | Control Group | 25 | 100 |
| Total, serious adverse events | Intervention Group | 0 | 93 |
| Total, serious adverse events | Control Group | 0 | 100 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33759389 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention Group vs Control Group: deaths from any cause | Trial comparisons |
| Intervention Group vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03374956
GET https://conductscience.org/api/trials/v1/NCT03374956/registered